Search results for "coagulation factor"

showing 10 items of 45 documents

Screening for multiple hereditary hypercoagulability factors using the amplification refractory mutation system

2003

Many hereditary factors have been implicated in the development of arterial and/or venous thromboembolic diseases. A number of these risk factors can be identified by the amplification refractory mutation system (ARMS). However, the underlying technical conditions for performing ARMS are highly variable, and depend on which risk factors are being analyzed. We have now developed a novel ARMS-based system to simultaneously screen for multiple hypercoagulability factors under identical PCR conditions. This can greatly simplify the process of screening for hereditary hypercoagulability.

GeneticsBase SequenceGenetic Carrier ScreeningHomozygoteGenetic Carrier ScreeningSingle-strand conformation polymorphismBlood ProteinsHematologyBlood Coagulation DisordersBiologymedicine.diseaseThrombophiliaBioinformaticsPolymerase Chain ReactionThrombosisBlood Coagulation FactorsRefractoryMutation (genetic algorithm)medicineCoagulopathyHumansMass ScreeningRisk factorDNA PrimersThrombosis Research
researchProduct

Characterization of a partial exon 9/intron 9 deletion in the coagulation factor XII gene (F12) detected in two Turkish families with hereditary angi…

2014

Geneticsbiologybusiness.industrySequence analysisIntronHematologyGeneral MedicineCoagulation Factor XIImedicine.diseasePhenotypeMolecular biologyC1-inhibitorExonHereditary angioedemabiology.proteinMedicinebusinessGeneGenetics (clinical)Haemophilia
researchProduct

Reversal of rivaroxaban-induced alterations on hemostasis by different coagulation factor concentrates – in vitro studies with steady and circulating…

2015

BACKGROUND: Despite the good safety of rivaroxaban, there is limited information on strategies for urgent reversal of its antihemostatic effects.Methods and Results:Alterations of hemostasis induced by rivaroxaban (230 ng/ml) were assessed by using several tests applied to steady and circulating human blood. Effects on thrombin generation (TG) and thromboelastometry (TEM) parameters were measured. Modifications in platelet adhesive, aggregating and procoagulant activities were evaluated in studies with circulating blood. The potential reversal of prothrombin complex concentrates (PCCs; 50 IU/kg), activated PCCs (aPCCs; 75 IU/kg), or recombinant factor VIIa (rFVIIa; 270 μg/kg) was evaluated.…

HemostàsiaPharmacologyFibrinAssaigs clínics de medicamentsRivaroxabanMedicineHumansPlateletFactor VIIIaCoagulació sanguíniaRivaroxabanHemostasisFactor VIIIbiologybusiness.industryDrugsDrug testingGeneral MedicineBlood coagulationBlood Coagulation FactorsThromboelastometryCoagulationRecombinant factor VIIaHemostasisAnesthesiabiology.proteinCardiology and Cardiovascular MedicinebusinessPerfusionMedicamentsmedicine.drugCirculation journal : official journal of the Japanese Circulation Society
researchProduct

The Effect of Fluctuating Temperature on the Stability of Turoctocog Alfa for Hemophilia A

2019

Abstract Background and objective Factor VIII (FVIII) is indicated for the prevention or treatment of bleeding in patients with hemophilia A. FVIII product stability under high and fluctuating temperatures is important, particularly for patients who reside in, or travel to, regions with high ambient temperatures, as they may remove their product from the refrigerator and return it, unused, multiple times. We evaluated the effect of variable temperature storage conditions, including up to 40 °C, on the stability of the recombinant FVIII product, turoctocog alfa. Methods Turoctocog alfa dry powder stability was assessed when moved between storage conditions of 5 °C (ambient humidity) and 40 °…

Hot TemperatureTime FactorsDrug StoragePharmacology toxicologyHemophilia A030226 pharmacology & pharmacy03 medical and health sciences0302 clinical medicineAnimal scienceDrug StabilityAmbient humidityHumansPotencyRelative humidityIn patientOriginal Research Article030203 arthritis & rheumatologyPharmacologyFactor VIIIChemistrylcsh:RM1-950Turoctocog alfaCoagulation Factor VIII Room TemperatureStability Turoctocog-alfaRecombinant ProteinsCold TemperatureMolecular Weightlcsh:Therapeutics. PharmacologyDry powderOxidation-ReductionDrugs in R&D
researchProduct

Response to "Is the Reg3α (HIP/PAP) Protein Really an Obesogenic Factor?"

2015

Peer Reviewed

Male0301 basic medicinePhysiologyClinical BiochemistryeducationMEDLINEPancreatitis-Associated ProteinsBiologyClinical biochemistry03 medical and health sciences0302 clinical medicineAnimalsHumansObesityPancreatitis-Associated ProteinsAnimalProteinMedicine (all)ProteinsCell BiologyBlood coagulation factorsBlood Coagulation Factors030104 developmental biology030220 oncology & carcinogenesisProteins metabolismImmunologyFemaleBlood Coagulation FactorHuman
researchProduct

Acquired inhibitors of clotting factors: AICE recommendations for diagnosis and management

2015

MaleAutoantibodies; Blood Coagulation Factor Inhibitors; Female; Humans; Male; Hemophilia A; Immunology and Allergy; HematologyBlood Coagulation Factor InhibitorsHumansImmunology and AllergyBlood Coagulation Factor InhibitorFemaleHematologyRecommendationHemophilia AAutoantibodieHumanAutoantibodies
researchProduct

Coagulation and inflammation in long‐term cancer survivors: results from the adult population

2018

Essentials The increase of cancer survival remains curtailed by cardiovascular mortality. We studied a large range of inflammatory and coagulation biomarkers in long-term cancer survivors. Cancer history has an important impact on mortality independent of cardiovascular risk factors. Fibrinogen and von Willebrand factor are potential biomarkers in survivors of increased mortality. Summary Background The advances in cancer treatment and detection of early cancer have resulted in a steady increase in the number of of cancer survivors over the years. However, because of the long-term toxic effects of chemotherapy and radiotherapy, the incidence of cardiovascular disease (CVD) is increasing in …

MaleOncologyTime Factorsmedicine.medical_treatmentDiseasecoagulation factors030204 cardiovascular system & hematologyFibrinogen0302 clinical medicineCancer Survivorscardiovascular diseaseRisk FactorsGermanyProspective StudiesRISKIncidence (epidemiology)survivorsHematologyMiddle AgedPrognosisCARDIOVASCULAR-DISEASECardiovascular Diseases030220 oncology & carcinogenesisCohortFemaleHEALTHInflammation Mediatorsmedicine.drugAdultmedicine.medical_specialtyVON-WILLEBRAND-FACTORRisk AssessmentOVARIAN-CANCER03 medical and health sciencesInternal medicinevon Willebrand FactormedicinecancerHumansCOHORTBlood CoagulationMETAANALYSISAgedInflammationProportional hazards modelbusiness.industryMORTALITYFibrinogenCancermedicine.diseaseRadiation therapyATHEROSCLEROSISPLASMA-FIBRINOGENOvarian cancerbusinessBiomarkersJournal of Thrombosis and Haemostasis
researchProduct

Activated prothrombin complex concentrate (FEIBA® ) in acquired haemophilia A: a large multicentre Italian study - the FAIR Registry

2019

MalePediatricsmedicine.medical_specialtyhaemophiliacoagulation factors030204 cardiovascular system & hematologyHemophilia AHaemophilia03 medical and health sciences0302 clinical medicineAcquired haemophiliaHumansMedicinecoagulation factorProspective StudiesRegistriesProspective cohort studyActivated prothrombin complex concentrateRetrospective Studiesbleeding disorders; coagulation factors; factor VIII; haemophilia; Blood Coagulation Factors; Female; Hemophilia A; Humans; Italy; Male; Prospective Studies; Retrospective Studies; Registriesbleeding disordersbleeding disorderbusiness.industryRetrospective cohort studyHematologymedicine.diseaseBlood Coagulation FactorsItalyfactor VIIIFemalebusiness030215 immunologyBritish Journal of Haematology
researchProduct

Replacement therapy for bleeding episodes in factor VII deficiency: A prospective evaluation

2013

Patients with inherited factor VII (FVII) deficiency display different clinical phenotypes requiring ad hoc management. This study evaluated treatments for spontaneous and traumatic bleeding using data from the Seven Treatment Evaluation Registry (STER). One-hundred one bleeds were analysed in 75 patients (41 females; FVII coagulant activity <1-20%). Bleeds were grouped as haemarthroses (n=30), muscle/subcutaneous haematomas (n=16), epistaxis (n=12), gum bleeding (n=13), menorrhagia (n=16), central nervous system (CNS; n=9), gastrointestinal (GI; n=2) and other (n=3). Of 93 evaluable episodes, 76 were treated with recombinant, activated FVII (rFVIIa), eight with fresh frozen plasma (FFP), s…

MaleRegistrieTime FactorsFactor VII Deficiency030204 cardiovascular system & hematologyReplacement therapyProspective evaluationchemistry.chemical_compound0302 clinical medicineMedicineProspective StudiesRegistriesYoung adultProspective cohort studyFactor VII deficiencyChildHematologyFactor VIIHematologyMiddle AgedRecombinant ProteinBlood Coagulation FactorsRecombinant ProteinsTreatment OutcomeCoagulantChild PreschoolFemaleBlood Coagulation FactorHumanAdultmedicine.medical_specialtyAdolescentTime FactorHemorrhageBlood Component TransfusionFactor VIIaBleeds; Factor VII deficiency; Replacement therapy; Adolescent; Adult; Aged; Blood Coagulation Factors; Child; Child Preschool; Coagulants; Drug Administration Schedule; Factor VII Deficiency; Factor VIIa; Female; Hemorrhage; Humans; Infant; Infant Newborn; Male; Middle Aged; Prospective Studies; Recombinant Proteins; Registries; Time Factors; Treatment Outcome; Young Adult; Blood Component Transfusion; HematologyDrug Administration Schedule03 medical and health sciencesYoung AdultInternal medicineHumansAgedBleeding episodesbusiness.industryCoagulantsInfant NewbornInfantSurgeryProspective StudieTreatment evaluationchemistryBleedbusiness030215 immunology
researchProduct

Increased Activity of Coagulation Factor XII (Hageman Factor) Causes Hereditary Angioedema Type III

2006

International audience; Hereditary angioedema (HAE) is characterized clinically by recurrent acute skin swelling, abdominal pain, and potentially life-threatening laryngeal edema. Three forms of HAE have been described. The classic forms, HAE types I and II, occur as a consequence of mutations in the C1-inhibitor gene. In contrast to HAE types I and II, HAE type III has been observed exclusively in women, where it appears to be correlated with conditions of high estrogen levels--for example, pregnancy or the use of oral contraceptives. A recent report proposed two missense mutations (c.1032C-->A and c.1032C-->G) in F12, the gene encoding human coagulation factor XII (FXII, or Hageman factor…

MaleTime FactorsKinins030204 cardiovascular system & hematologyMESH: Founder Effect[SDV.IMM.II]Life Sciences [q-bio]/Immunology/Innate immunityLinkage Disequilibrium0302 clinical medicineMissense mutationHereditary Angioedema Type IIIGenetics(clinical)MESH: Models GeneticGenetics (clinical)MESH: Heterozygote0303 health sciencesFactor XII[SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/HematologyFounder EffectMarkov ChainsPedigree3. Good healthMESH: Linkage DisequilibriumFactor XIIHereditary angioedemaFemalemedicine.symptomMESH: Factor XIIHeterozygotemedicine.medical_specialtyMESH: MutationMESH: PedigreeMESH: Bayes TheoremCoagulation Factor XIIBiology03 medical and health sciencesMESH: Markov ChainsReportInternal medicinemedicineGeneticsHumansMESH: AngioedemaAngioedema030304 developmental biologyMESH: HumansModels GeneticAngioedemaHaplotypeMESH: Time FactorsBayes TheoremHeterozygote advantageMESH: Haplotypesmedicine.diseaseMESH: KininsMESH: MaleEndocrinologyHaplotypesMutationImmunologyMESH: Microsatellite RepeatsMESH: FemaleMicrosatellite RepeatsThe American Journal of Human Genetics
researchProduct